ePlus PLUS Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value at other companies

RepligenRGEN

$155.80—

Cal-Maine FoodsCALM

$54.10+21.0%

RepligenRGEN

$129.34—

PNC Financial ServicesPNC

$190.93+34.7%

The Baldwin Insurance Group, Inc.BWIN

$24.13-29.3%

Boston BeerSAM

$210.34-10.1%

Other financials

Income statement

See full

Revenue$581.6M+21.7%

Gross profit$147.1M+10.7%

Operating income$37.6M+52.0%

Net income$25.0M+14.9%

EPS (diluted)$0.95+14.5%

Balance sheet

See full

Cash & equivalents$410.8M+5.5%

Total debt$16.3M-80.9%

Total equity$1.1B+10.1%

Total assets$1.8B-4.2%

Cash flow

See full

Operating cash flow-$87.4M-233%

CapEx$1.2M-36.5%

Free cash flow-$30.2M-119%

Valuation

See full

Market cap$2.11B+22.3%

Profitability

See full

Gross margin25.2%-0.4pp

Operating margin6.8%+1.8pp

Net margin5.4%+0.2pp

FCF margin-10.4%-26.4pp

Returns & leverage

See full

Return on equity13%+1.8pp

Debt / equity0×-0.1×

Current ratio2.2×+0.5×

Where this comes from

Reported directly by ePlus in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.

The official record: ePlus’s 10-Q, filed February 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about ePlus's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ePlus's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?: ePlus (PLUS) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value of $73.63 in Q4 2025.